By Fineline Cube 
Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75 billion, a 2% increase year-on-year (YOY). For the full year, revenues rose 3% YOY to USD 10.64 billion.
Q4 Segment Performance
- Medical Products & Therapies: Sales grew 1% YOY to USD 1.314 billion, driven by strong demand for the Novum IQ infusion pump, parenteral nutrition products, and Advanced Surgery offerings. However, IV solutions sales declined.
- Pharmaceuticals: Sales jumped 8% YOY to USD 643 million, fueled by double-digit growth in specialty injectables and robust Drug Compounding performance.
- Healthcare Systems & Technologies: Sales dipped 1% YOY to USD 784 million, as previously anticipated.
Full-Year Segment Performance
- Medical Products & Therapies: USD 5.207 billion (+5%)
- Pharmaceuticals: USD 2.411 billion (+7%)
- Healthcare Systems & Technologies: USD 2.951 billion (-2%)
Kidney Care Business
Baxter completed the sale of its Kidney Care business during the year.-Fineline Info & Tech